Hsp–peptide complexes present in the cells of each tumor are characterized by an individual antigenic and neoantigenic pattern, a peptide “fingerprint”, unique for specific cancer which can be used in personalized therapy approaches, where the surgical resection of the tumor, followed by the isolation of the complexes, is a basis for anticancer vaccine production. The gene discussed is HSP90B2P; the disease is neoplasm.